Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley +1 more source
Expression of Concern: Dietary Compound Isoliquiritigenin Inhibits Breast Cancer Neoangiogenesis via VEGF/VEGFR-2 Signaling Pathway. [PDF]
PLOS One Editors.
europepmc +1 more source
A tunable bifunctional surface is developed by combining Fc‐binding peptides and RGD motifs to present oriented antibodies alongside integrin‐mediated signaling. The platform selectively captures endothelial colony‐forming cells while promoting their adhesion and proliferation.
Hugo A. Level +5 more
wiley +1 more source
Exploring market-approved azoles as potential breast cancer therapeutics targeting the VEGFR-2 biotarget. [PDF]
Atta AM +13 more
europepmc +1 more source
VEGFR-2 in Endothelial Differentiation and Vascular Organization [Elektronisk resurs]
The cardiovascular system is the first functional organ to develop during embryogenesis. As the embryo reaches above a certain size, passive diffusion of gases and nutrients is no longer compatible with efficient growth. During embryogenesis, endothelial
Bautch, Victoria, +3 more
core
Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best +5 more
wiley +1 more source
Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab. [PDF]
Kawczak P, Bączek T.
europepmc +1 more source
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
(<i>E</i>)-4-(4-Acrylamidophenoxy)-<i>N</i>-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model. [PDF]
Velma GR +11 more
europepmc +1 more source
A dual‐network bFGF@CB‐gel integrates: i) ChSMA scaffold (mechanical support/BMSCs delivery); ii) BC carrier (sustained bFGF release via EGFL/Itga2b and COMP/PI3K/AKT for adhesion/osteogenesis); iii) bFGF/PI3K/AKT/eNOS for angiogenesis. This rational, synergistic design addresses CSD bone regeneration challenges.
Yunze Feng +12 more
wiley +1 more source

